

Joint Working EXECUTIVE SUMMARY

Published on www.astrazeneca.co.uk

Joint Working between AstraZeneca UK Ltd and [Partner Name]

Document Number 195-1-ES

Date of Preparation Jan 2025

Project title	Historic Heart Failure Patient Review & Optimisation to current best practice treatment
Aims and Objectives	Clinical review of existing Heart Failure patients (2020-2023) in the QE2 Hospital, Kings Lynn known not to be prescribed GDMT. Increase uptake of GDMT (including SGLT2i) optimisation in both HFrEF and HFpEF patients. Ensure all patients with Heart Failure in the QE2 catchment are correctly optimised on relevant treatment. Decrease readmission and improve the mortality rate of patients with Heart Failure in catchment area. 800 Heart Failure Patient reviews over 2 years (9 per week @ 1.5 sessions of 6 patient clinics p/w)
Anticipated benefits	1. Possible improvement in QoL 2. Optimised treatment 3. Increased access to specialist team 1. Capacity relief for both Primary and Secondary Care. 2. Opportunity to provide recommended SOC to all HF patients and demonstrate equity of care 3. Ability to identify high risk patients. 4. Platform to promote SOC across Hospital Departments
Timeline	The project will commence on the 01 Jan 2025 and will continue for a duration of [DateEnd] months.
References	[References]